norfloxacin has been researched along with amphotericin b in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Kalinin, AA; Kulik, NV; Mamedov, VA; Voloshina, AD; Zobov, VV | 1 |
| Batchu, H; Batra, S; Mishra, A; Shukla, PK; Singh, P; Srivastava, K | 1 |
| Chopra, S; Kushwaha, P; Modukuri, RK; Pasupuleti, M; Rao, KB; Sashidhara, KV; Shukla, PK; Singh, P; Soni, I | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Zhang, B | 1 |
| Askar, AA; El-Khalafawy, A; Makhlouf, AH; Ragab, A; Salem, MA | 1 |
| Capito, JE; El-Manawaty, MA; George, RF; Girgis, AS; Panda, SS; Salman, A; Samir, A; Thomas, SJ | 1 |
| Aerdts, SJ; Clasener, HA; Festen, J; van Dalen, R; van Lier, HJ; Vollaard, EJ | 1 |
| Bercy, P; De Beule, F; Ferrant, A | 1 |
| Dan, K; Ito, T; Iwakiri, K; Nomura, T; Ogata, K; Tanabe, Y; Yamada, T | 1 |
| Clasener, HA; Joosten, HJ; van Griethuysen, AJ; Vollaard, EJ; Zambon, JV | 1 |
| Haralambie, E; Schmidt-Weinmar, A | 1 |
| Petrou, MA; Rogers, TR | 1 |
| Boyce, ST; Holder, IA; Warden, GD | 1 |
| Dan, K; Nomura, T; Yamada, T | 1 |
| Bottema, JT; Bruining, HA; Haagsma, EB; Klompmaker, IJ; Laseur, M; Maring, JK; Metselaar, HJ; Slooff, MJ; TenVergert, EM; van Enckevort, PJ; Winter, HL; Zwaveling, JH | 1 |
2 review(s) available for norfloxacin and amphotericin b
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Triazoles | 2019 |
4 trial(s) available for norfloxacin and amphotericin b
| Article | Year |
|---|---|
Antibiotic prophylaxis of respiratory tract infection in mechanically ventilated patients. A prospective, blinded, randomized trial of the effect of a novel regimen.
Topics: Administration, Topical; Amphotericin B; Bacteria; Cefotaxime; Colistin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Intensive Care Units; Male; Middle Aged; Norfloxacin; Oropharynx; Prospective Studies; Respiration, Artificial; Respiratory Tract Infections; Severity of Illness Index; Stomach | 1991 |
Prevention of catheter-associated gram-negative bacilluria with norfloxacin by selective decontamination of the bowel and high urinary concentration.
Topics: Aged; Aged, 80 and over; Amphotericin B; Bacteriuria; Candida albicans; Digestive System; Feces; Female; Gram-Negative Bacteria; Hip Fractures; Humans; Norfloxacin; Urinary Catheterization | 1989 |
Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B.
Topics: Administration, Oral; Adult; Amphotericin B; Antineoplastic Agents; Bacterial Infections; Drug Combinations; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Leukemia; Male; Middle Aged; Mycoses; Norfloxacin | 1993 |
Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients.
Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Decontamination; Digestive System; Double-Blind Method; Female; Humans; Liver Transplantation; Male; Mycoses; Norfloxacin; Postoperative Complications; Tobramycin | 2002 |
13 other study(ies) available for norfloxacin and amphotericin b
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety.
Topics: Animals; Anti-Infective Agents; Bacteria; Drug Design; Female; Fungi; Imidazoles; Male; Mice; Microbial Sensitivity Tests; Pyridinium Compounds | 2013 |
Synthesis and evaluation of new diaryl ether and quinoline hybrids as potential antiplasmodial and antimicrobial agents.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antimalarials; Bacteria; Dose-Response Relationship, Drug; Ethers; Fungi; Microbial Sensitivity Tests; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum; Quinolines; Structure-Activity Relationship | 2014 |
Novel Chalcone-Thiazole Hybrids as Potent Inhibitors of Drug Resistant Staphylococcus aureus.
Topics: | 2015 |
One-pot synthesis and molecular docking of some new spiropyranindol-2-one derivatives as immunomodulatory agents and in vitro antimicrobial potential with DNA gyrase inhibitor.
Topics: Anti-Bacterial Agents; Antifungal Agents; Arylsulfonates; DNA Gyrase; Dose-Response Relationship, Drug; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Immunologic Factors; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Spiro Compounds; Structure-Activity Relationship; Topoisomerase Inhibitors | 2020 |
Synthesis, pharmacological profile and 2D-QSAR studies of curcumin-amino acid conjugates as potential drug candidates.
Topics: Amino Acids; Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Candida albicans; Carrageenan; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Edema; Mice; Microbial Sensitivity Tests; Molecular Structure; Pain; Pseudomonas aeruginosa; Quantitative Structure-Activity Relationship; Rats; Salmonella typhi; Spleen; Staphylococcus aureus; Streptococcus pyogenes; Ulcer | 2020 |
The effectiveness of a preventive regimen on the periodontal health of patients undergoing chemotherapy for leukemia and lymphoma.
Topics: Acyclovir; Amphotericin B; Ceftazidime; Chlorhexidine; Dental Plaque Index; Fluconazole; Humans; Immunosuppression Therapy; Ketoconazole; Leukemia; Lymphoma; Miconazole; Norfloxacin; Periodontal Diseases; Periodontal Index; Tooth Loss; Vancomycin | 1991 |
Two cases of disseminated Trichosporon beigelii infection treated with combination antifungal therapy.
Topics: Adult; Amphotericin B; Drug Combinations; Flucytosine; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Miconazole; Mycoses; Norfloxacin; Trichosporon | 1990 |
Infections after experimental cadaver bone marrow transplantation in beagle dogs. Transplantations with and without selective gastrointestinal decontamination.
Topics: Amphotericin B; Animals; Bacterial Infections; Bone Marrow Transplantation; Digestive System; Dogs; Norfloxacin; Premedication | 1988 |
In-vitro activity of antifungal agents in combination with four quinolones.
Topics: 4-Quinolones; Amphotericin B; Anti-Infective Agents; Antifungal Agents; Candida; Candida albicans; Ciprofloxacin; Drug Combinations; Enoxacin; Flucytosine; Mepartricin; Nalidixic Acid; Naphthyridines; Norfloxacin; Quinolines; Saccharomyces cerevisiae | 1988 |
Noncytotoxic combinations of topical antimicrobial agents for use with cultured skin substitutes.
Topics: Administration, Topical; Amphotericin B; Burns; Candida; Cells, Cultured; Ciprofloxacin; Culture Techniques; Drug Therapy, Combination; Enterobacteriaceae; Fibroblasts; Humans; Keratinocytes; Microbial Sensitivity Tests; Norfloxacin; Nystatin; Skin; Skin, Artificial; Staphylococcus aureus | 1995 |